Roivant股价盘前飙升15.8%,实验性药物对罕见皮肤病显效及三季度业绩提振市场信心

美股速递
Feb 06

Roivant Sciences Ltd. (ROIV) 股价在盘前交易时段大幅跃升15.8%,此番强劲表现主要受到两大利好因素驱动:其一,公司旗下实验性药物在针对一种罕见皮肤病的临床试验中展现出积极疗效;其二,公司最新公布的第三季度财务业绩超出市场预期。这两项进展共同点燃了投资者的热情,推动股价显著上扬。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10